Biofrontera Inc.

What they do

Biofrontera develops and commercializes photodynamic therapy (PDT) in dermatology. Its lead product is Ameluz, used with the RhodoLED XL lamp for the treatment of actinic keratosis. The company sells in the United States and has been restructured since a strategic transaction with Biofrontera AG closed in October 2025.

Revenue drivers

• Ameluz — Ameluz is the company's principal product, a topical photosensitizer used in PDT for actinic keratosis. It accounts for the substantial majority of net product revenue, which totaled $41.7 million in 2025 and $22.1 million in the first half of 2026.
• RhodoLED XL lamp — The RhodoLED XL lamp is used with Ameluz to deliver the light activation step of PDT. The installed lamp base is primarily unaffected by an ITC exclusion order, though new sales of the XL lamp were restricted after July 7, 2026.
• PDT pipeline indications — The company is developing Ameluz for additional indications, including superficial basal cell carcinoma (sBCC), actinic keratosis on extremities/neck/trunk, and acne. These are not yet commercial contributors.

Recent performance

For the second quarter of 2026, net product revenue was $12.0 million, up 32.9% from $9.0 million a year earlier. Gross margin was 80%, up from 71%, and net loss narrowed to $0.6 million, or $(0.05) per share, from a net loss of $5.3 million, or $(0.57) per share. Adjusted EBITDA was $(0.2) million versus $(5.1) million in the prior-year period. For the first half of 2026, revenue was $22.1 million, up 25.4%, with a net loss of $5.4 million and operating cash use of $1.7 million versus $7.2 million a year earlier. The revenue increase included a price increase and unit volume growth, partly from customer order timing ahead of potential ITC-related supply restrictions.

Strategy

Management is focused on growing Ameluz demand, improving gross margin through a lower Ameluz cost structure established after the October 2025 strategic transaction with Biofrontera AG, and disciplined cost management. The company is pursuing a remediation plan to resume selling a modified version of the RhodoLED XL lamp and expects to launch in Q1 2027 for superficial basal cell carcinoma if approved, following a PDUFA date in late September 2026. It is also advancing pipeline indications including AK on extremities/neck/trunk and acne. A stated priority is reaching cash flow breakeven in 2026.

Risks

• ITC exclusion order on RhodoLED XL — An International Trade Commission exclusion order related to the RhodoLED XL lamp took effect July 7, 2026, restricting new sales of that lamp and creating a loss contingency the company estimates using a bottom-up cost model.
• Loss contingency estimate sensitivity — The recorded accrual for the ITC matter is sensitive to assumptions including labor and travel costs, remediation unit costs and foreign exchange rates, regulatory pathway, and the timing and outcome of suspended orders, and any change could be material.
• History of net losses and cash use — Biofrontera reported net losses in each year from 2021 through 2025 and used cash in operating activities in each of those years, including $13.4 million in 2025.
• Order timing and customer concentration — Second quarter 2026 revenue growth was partly driven by order timing from certain customers ahead of potential supply restrictions, which may shift revenue between periods rather than reflect total demand.

Outlook

Management said it continues to target cash flow breakeven in 2026 and expects the ITC-related shift in orders to the second quarter not to impact full-year 2026 revenue goals. It has a PDUFA date in late September 2026 for superficial basal cell carcinoma and, if approved, expects to launch in Q1 2027, which it says would make Ameluz the first PDT in the United States approved for the treatment of cancerous tumors. The company also cited positive Phase III results in AK on the extremities/neck/trunk and encouraging Phase 2B data in acne.